Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma

Oncogene

Volumn 33, Issue 50, 2014, Pages 5697-5705

  Kang, Z ^a,b   Yu, Y ^a   Zhu, Y J ^a   Davis, S ^a   Walker, R ^a   Meltzer, P S ^a   Helman, L J ^a   Cao, L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

antibody therapy; drug combination; drug resistance; IGF1R; IGFBP2; rhabdomyosarcoma

Indexed keywords

5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MORPHOLINE DERIVATIVE; NVP-BKM120; PYRIMIDINE DERIVATIVE; R-1507 MONOCLONAL ANTIBODY; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C RECEPTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; DOWN REGULATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; RHABDOMYOSARCOMA; SCID MOUSE; TREATMENT FAILURE; TUMOR CELL LINE;

AMINOPYRIDINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; MORPHOLINES; PYRIMIDINES; RECEPTOR, IGF TYPE 1; RHABDOMYOSARCOMA; TREATMENT FAILURE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888344894     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.509     Document Type: Article

References (44)

1. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007; 6: 821-833.
2. Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochimica et Biophysica Acta 2006; 1766: 1-22.
3. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev 2008; 8: 915-928.
4. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev 2012; 12: 159-169.
5. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR et al. Gene expression profiles in normal and cancer cells. Science (New York, NY) 1997; 276: 1268-1272.
6. Hendrickson AW, Haluska P. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Curr Opin Investig Drugs 2009; 10: 1032-1040.
7. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006; 94: 465-468.
8. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008; 12: 589-603.
9. Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 2005; 9: 753-768.
10. Olmos D, Basu B, de Bono JS. Targeting insulin-like growth factor signaling: rational combination strategies. Mol Cancer Ther 2010; 9: 2447-2449.
11. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009; 28: 3009-3021.
12. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010; 11: 129-135.
13. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27: 5800-5807.
14. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011; 29: 4541-4547.
15. Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMCA12, with or without cetuximab, in patients with cetuximab- or panitumumabrefractory metastatic colorectal cancer. J Clin Oncol 2010; 28: 4240-4246.
16. Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, Schneider CP et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011; 29: 4574-4580.
17. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012; 104: 975-981.
18. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev 2003; 3: 685-694.
19. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990; 1: 325-331.
20. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010; 70: 6497-6508.
21. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091-3102.
22. Petricoin 3rd EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007; 67: 3431-3440.
23. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008; 68: 8039-8048.
24. Mayeenuddin LH, Yu Y, Kang Z, Helman LJ, Cao L. Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L). Oncogene 2010; 29: 6367-6377.
25. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H et al. Molecular classification of rhabdomyosarcoma - genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol 2009; 174: 550-564.
26. Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. J Clin Oncol 2010; 28: 1240-1246.
27. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 500-504.
28. Bhat RV, Engber TM, Zhu Y, Miller MS, Contreras PC. Identification of insulin-like growth factor binding protein-2 as a biochemical surrogate marker for the in vivo effects of recombinant human insulin-like growth factor-1 in mice. J Pharmacol Exp Ther 1997; 281: 522-530.
29. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007; 104: 5563-5568.
30. Arai T, Busby W Jr, Clemmons DR. Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 1996; 137: 4571-4575.
31. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-854.
32. Hoflich A, Lahm H, Blum W, Kolb H, Wolf E. Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett 1998; 434: 329-334.
33. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002; 20: 833-841.
34. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-1940.
35. Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM et al. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res 2010; 70: 8770-8781.
36. Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 2010; 70: 7221-7231.
37. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011; 30: 2730-2740.
38. Hoeflich A, Wu M, Mohan S, Foll J, Wanke R, Froehlich T et al. Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology 1999; 140: 5488-5496.
39. Mathews LS, Hammer RE, Behringer RR, D'Ercole AJ, Bell GI, Brinster RL et al. Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 1988; 123: 2827-2833.
40. Hedbacker K, Birsoy K, Wysocki RW, Asilmaz E, Ahima RS, Farooqi IS et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab 2010; 11: 11-22.
41. Martin JL, Baxter RC. Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/ AKT/mammalian target of rapamycin pathway. Endocrinology 2007; 148: 2532-2541.
42. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001; 61: 8601-8610.
43. Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L et al. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for highgrade gliomas. Proc Natl Acad Sci USA 2009; 106: 16675-16679.
44. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811-818.